Lindahl assisted Newbury Pharmaceuticals AB with listing
Lindahl assisted Newbury Pharmaceuticals AB with listing of the company's shares on Nasdaq First North Growth Market.
In connection with the listing, a new share issue of approximately SEK 50 million was carried out for the general public in Sweden, Norway, Denmark and Finland as well as for institutional investors. There was a great deal of interest in the offer, which was oversubscribed. The first day of trading is 4 February.
Lindahl acted as legal advisor to Newbury in connection with the listing and raising capital and the team consisted mainly of Johan Herrström and Pontus Söderberg.
About our client Newbury
Newbury provides prescription medicines to patients and healthcare providers in the Scandinavian market. The company focuses on speciality medicines and proprietary brands with particular focus on oncology, rare diseases and neurology.
Do you want to know more? Contact:
Johan Herrström
Managing Partner Malmö | AdvokatPontus Söderberg
Senior Associate | AdvokatCarousel items
-
News articles
6/25/2026
Lindahl recognised in IP Stars 2026
Lindahl advances to Tier 2 in Copyright & related rights in IP Stars 2026, retains strong rankings in trade mark law, and sees several lawyers recognised with individual awards.
-
Cases and transactions
6/23/2026
Lindahl acts as legal adviser to Medivir in a private placement of approximately 140 MSEK
Lindahl acted as legal adviser to Medivir in connection with an oversubscribed private placement of SEK 140 million for the clinical development of the drug candidate MIV-711.
-
Knowledge
6/15/2026
Properly prepared — contract law in the new security landscape
Preparedness laws such as the Rationing Act and the Requisition Act can alter your contracts from one day to the next. Lindahl cuts through the terminology in the new security landscape.
-
Portraits
6/2/2026
Björn on M&A at Lindahl: "No two deals are alike"
Björn Andersson on M&A at Lindahl: how each transaction brings new challenges – and why no two deals are alike. Read about his experience and approach.
-
Read more news and insights?
